STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

BAM15

Also known as

BAM-15 · BAM 15 · mitochondrial uncoupler BAM15 · mitochondrial protonophore BAM15 · oxadiazolo-pyrazine uncoupler BAM15 · N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine · N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine · CAS 210302-17-3 · “safer DNP” BAM15 (community nickname)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral; rare injection logs Metabolic research compounds

Systemic — an oral mitochondrial uncoupler in fat-loss discussion; mouse liver/adipose findings do not prove human safety or spot-fat effects.

What people say BAM15 is a mitochondrial uncoupler discussed for fat loss, not a peptide or approved weight-loss medicine. Mouse findings fuel “safer DNP” claims, but do not establish a safe human therapeutic window. Doses people talk about
Lower oral chart culture5–10 mg once daily

An older exploratory self-report/vendor-chart band, not validated efficacy or an endorsed starting dose.

Intermediate oral discussion15–30 mg/day

Once in the morning or split BID about 8–12 hours apart in older summaries; mouse half-life does not validate that spacing.

Higher / conflicting claims40–60 mg/day; 250 mg capsules

Separate camps, not equivalent regimens. Other posts claim 400 mg+, 500–1000 mg or even 2 g/day (1 g AM / 1 g PM); these are unvalidated marketing/self-use claims with heat and exercise-intolerance cautions.

Mouse mg/kg, food percentages and human capsule claims are separate. The full notes preserve 200 mg EOD, 150–300 mg/day and rare injection accounts; none establishes a safe efficacy ladder.

Half-life & effect duration

Half-life in the body
  • Oral single dose · miceAbout 1.7 hours
  • Food-admix study · miceAbout 3 hours
  • Human community / blog estimateAbout 4–6 hours
Felt duration people report
  • One BAM15 + SANA accountNothing initially; warmth in week 1; weight or waist changes over 3 weeks
  • Other accountsNo clear effect, strong warmth, or night sweats
Timing context & sources
How it may feel Reports conflict: nothing, warmth or night sweats, thirst, fatigue and worse exercise tolerance all appear. Weight changes over weeks often involve diet or other agents; neither heat nor no heat proves efficacy or safety.
Cycles people discuss Community logs discuss 1–2-week tolerability checks and 4–8-week cut-length blocks, sometimes stopping earlier. Equal-time-off or multi-week breaks are lore, not validated human washouts; long-term safety is unknown. Timing Morning or split oral reports coexist with concern about later heat and sleep disruption. Workout timing also conflicts: one log preferred after training or the night before. Mouse half-lives do not validate these human schedules. Stacks SLU-PP compounds, GLPs, 5-Amino-1MQ and mitochondrial supplements recur in multi-agent logs. Their contribution and combined safety are unclear; stimulant, thyroid and DNP combinations carry explicit caution in the full notes. Access talk RUO oral only: Capsules and powder labeled research-use / not for human consumption. Not a compounded pharmacy uncoupler and not an approved fat-loss drug. Labs people mention Oral temperature + resting HR: Harm-reduction posts check temp a few times a day and watch RHR — uncoupler-class habit, not a BAM15 label. Watch for Class risk (uncouplers): Over-uncoupling can produce hyperthermia that does not respond to ordinary antipyretics, CV strain, rhabdomyolysis, organ failure — DNP’s human death and cataract history is the cautionary class tale. BAM15 mouse data look cleaner; human overdose series for BAM15 specifically are not established.
Related
SLU-PP-332SLU-PP-915

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 1.7 hours was measured after 10 mg/kg oral gavage in mice.

Alexopoulos reported about 67% oral bioavailability and 8.2 µM Cmax. Axelrod's separate 0.1% food-admix design reported about 3 hours with serum near 5 µM; continuous feeding differs from a single gavage.

Neither mouse design establishes human PK. The 0–3-hour oxygen-consumption response, 4-hour tissue sampling and multi-week metabolic changes are different endpoints.

  • Alexopoulos et al. — BAM15 reverses obesity in mice (opens in a new tab)Original article body, PK/results, figure captions and dosing methods read via Europe PMC full XML for PMC7224297: 10 mg/kg oral versus 1 mg/kg IV normalized PK; 50 mg/kg tissue distribution; chronic 0.05–0.15% diet experiments.Mouse plasma/distribution and metabolic outcomes only. Sampled tissue decline over four hours is not proof of complete clearance; no human PK conversion.
  • Axelrod et al. — BAM15 systemic uncoupling in obese mice (opens in a new tab)Original full-text Results around Figure 4A: 0.1% HFD admixture, about 85 mg/kg/day consumed, serum about 5 µM and approximately 3-hour half-life; relevant food-admix methods.Chronic mouse feeding context differs from isolated oral gavage. Cellular respiration persistence and serum parent half-life must not be combined as a human clock.

Felt duration people report

The checked human reports do not establish a dependable felt-duration window.

The same 70 mg BAM15 plus 250 mg SANA account describes initially nothing, warmth in week 1 and weight/waist changes over 3 weeks; another commenter was unsure of any effect.

Cross-posts are one account, not independent confirmation. Summer weather, co-use, diet and product identity confound attribution; neither a three-week course nor heat describes parent half-life.

  • SANA MVD1 and BAM15 — three-week combined-use account (opens in a new tab)Actual ztxrsg OP: 250 mg SANA MVD1 plus 70 mg BAM15 capsules, first days none, week-1 warmth, week-2 4.3 lb and week-3 total 6.7 lb loss; appetite/energy/sleep descriptions.Uncontrolled combined-use account in NYC summer. Cross-posted to r/Biohacking; not two independent users. Weight claims are neither measured expenditure nor isolated BAM15 efficacy.
  • SANA/BAM15 cross-post and uncertain-response comment (opens in a new tab)Actual same-author cross-post and visible ZangaPanga reply stating uncertainty about feeling anything or whether it is doing anything.OP duplicates the r/Biohackers account; counted once. Comment dose/form and observation interval are not established, so it supplies uncertainty rather than a quantitative comparison.

What people say 20

  • Community human claims: Sparse self-reports of easier deficit fat loss, night sweats/warmth, modest scale movement — heavily confounded by diet, training, stacks, and unknown purity; no controlled human fat-loss package. forumanecdote
  • Evidence honesty: Mouse metabolic package is real and citable; “safe DNP” branding oversells human risk unknown; gray-market mg labels ≠ assayed active. trialforum
  • 2025–26 diary split: Some r/BAM15 50–100 mg oral logs claim scale movement in a deficit with “no sides.” Others on 250–1000 mg 250-mg-capsules report little heat and a stuck scale, then call reta cheaper. Attribution is purity + calories. forumanecdote
  • SLU + BAM still the named mito pair: 16-day blend logs (tiny BAM mcg next to SLU) and 2026 BioBAM + SLU-PP-332 carts stay louder than solo BAM science. forum
  • Fat mass prevention (mice): Alexopoulos et al. — 0.05% w/w BAM15 in Western diet blocked >50% of fat-mass gain; 0.10–0.15% w/w fully prevented fat gain over ~8 days without lowering food intake or fat-free lean mass. animal
  • Fat mass reversal (mice): After ~4 weeks WD obesity conditioning, 0.1% w/w BAM15 for ~5 weeks → ~15% lower body weight vs WD controls, almost all from less fat, lean mass matched, same calorie intake; not lipid malabsorption (fecal TG/NEFA/chol unchanged). animal
  • Energy expenditure: Food-admix 0.1% raised dark-cycle oxygen consumption ~15% without more locomotion; acute oral 50 mg/kg and 100 mg/kg raised VO2 ~30% and ~50% in the first hour (10 mg/kg oral often null on OCR). animal
  • Fuel shift: Lower RER (more fat oxidation) in dark cycle on admix; ex vivo liver 14C-palmitate oxidation up ~51% 1 h after 100 mg/kg oral gavage. animal
  • No hyperthermia (mice, efficacious range): Core temperature flat after chronic oral admix and after acute oral doses up to solubility-limited ~200 mg/kg; IP acute temp also unchanged in Axelrod dosing. Mouse “no fever” is not a human safety certificate. animal
  • Lean mass sparring: Multiple DIO models: fat down, lean/muscle depots preserved; contrasts with some other uncouplers/calorie restriction that cut lean more. animal
  • Glucose / insulin: Prevented WD glucose intolerance at 0.05–0.15% w/w; reversed hyperinsulinemia and GTT defects within ~3 weeks of 0.1% admix after obesity conditioning. animal
  • Clamp (gold-standard mice): After ~6 weeks treatment, glucose infusion rate normalized toward chow; better muscle 2-DG uptake (gastroc/quad) and stronger insulin suppression of adipose NEFA vs WD. animal
  • Liver fat / lipids: Hepatic TG corrected toward chow; Oil Red O lipid staining reduced; plasma TG lower; inflammatory eicosanoid/docosanoid signals and 4-HNE down; GSH up (antioxidant signature). animal
  • Independent of weight loss alone (Axelrod): vs calorie-restricted weight-matched controls, BAM15 still improved body composition and glycemic control signals — EE mechanism, not just smaller mice. animal
  • Aged / sarcopenic obesity (mice): Dantas et al. 2022 — multi-week BAM15 in old obese mice: fat loss with improved muscle mass/strength narratives in secondary writeups (e.g. ~8% muscle, ~40% strength, >20% fat loss in popular summaries — verify primary for exact figures). animal
  • Lower-dose aged chow (preprint-style work): 0.033% admix ~8 weeks in 24-month mice — muscle/mitophagy endpoints studied; body/muscle mass not always shifted at that lower exposure. animal
  • db/db / head-to-head: Later comparative uncoupler screens report BAM15 among stronger performers on body weight, glucose, and liver steatosis in diabetic mouse models. animal
  • Semaglutide combo (mice): Chen et al. line — simultaneous calorie-intake targeting (semaglutide) + BAM15 EE raised weight/fat loss beyond either alone in published designs (~40 mg/kg/day BAM15-scale admix in one report). Preclinical only. animal
  • MASH / derivative adjacency: Parent BAM15 at 0.1% w/w ± MGL-3196 (resmetirom-class) in GAN MASH models; improved BAM15 analogs (e.g. SHS4121705, 10b at ~25 mg/kg/day oral) pursued for NAS/fibrosis without needing obesity doses. animal
  • Other preclinical hooks: Kidney ischemia–reperfusion protection (discovery-era IP work); anti-atherosclerosis oral ~85 mg/kg/day × 12 weeks designs; AMPK / macrophage NLRP3 adjacency in mechanistic papers. animal

Doses people talk about 20

  • Allometric caution: Naive scaling of ~50–85 mg/kg/day mouse food-admix implies multi-gram human-equivalents by simple mg/kg — that is not how vendors or cautious threads dose, and BSA scaling still is not a safety trial. Community oral culture sits far below raw mg/kg mouse numbers. forumtrial
  • Human oral — lowest exploratory band (self-report / vendor-chart culture): ~5–10 mg once daily oral discussed as a “start low” research-chem harm-reduction floor — not validated efficacy. forum
  • Human oral — common intermediate talk: ~15–30 mg/day oral, once morning or split BID ~8–12 h apart, is the most repeated “people actually run this” band in dosage-guide / self-report summaries. forum
  • Human oral — higher experimental talk: ~40–60 mg/day (and occasional higher) appears as “advanced” self-experiment territory with worse warmth, sweat, fatigue, and exercise-intolerance anecdotes; not evidence-based escalation. forumanecdote
  • Human oral — outlier lore: Social comments sometimes push ~200 mg EOD or claim “need large dose not like 25 mg”; other confused threads float hundreds-of-mg ranges borrowed from unrelated compounds — treat as unreliable noise. forumanecdote
  • Split-dosing rationale in discussion: Mouse t½ values around 1.7–3 hours accompany multi-daily or continuous food-exposure research. Community BID use is described as smoothing peaks versus one large bolus, but mouse kinetics do not validate human BID timing. The counter-argument remains that a second dose may disrupt sleep through perceived residual heat. animalforum
  • With food / fat: Lipophilic, low aqueous solubility → take-with-fat or lipid vehicle (MCT/oil) talk in influencer and handling threads; lab vehicles use organic co-solvents or diet matrix. forumanimal
  • Route hierarchy: Published chronic mouse = dietary admix; published acute = oral gavage or IP/IV for PK; community = oral powder/capsules almost exclusively; injectable BAM15 is rare anecdote, not literature standard for obesity. animalforum
  • Duration of daily exposure talk: 4–8 weeks on is common self-report block length; some stop earlier on sides. Continuous open-ended human use has no safety database. forum
  • Identity / assay risk: Low solubility + short t½ + gray-market powder means labeled mg ≠ guaranteed free active; under-dosed caps and wrong molecule both explain null logs. forum
  • 250 mg capsule camp (2026): BioBAM-style SKUs at 250 mg/cap made high-mg swallows the default bottle. r/BAM15 comments then argue “need 400 mg+ to notice” or run 500–1000 mg with little feel — opposite pole from 5–10 mg harm-reduction charts. forum
  • Gram-day influencer talk: August 2026 X posts told people to take ~2 g/day (1 g AM / 1 g PM) on 250 mg caps “for DNP-like effects.” That is marketing-dose lore, not a human PK band, and sits far above the older 15–30 mg forum cluster. forum
  • Looksmaxx / high-oral outliers: Some 2025 logs floated 150–300 mg/day as “min effective.” Uncontrolled, purity-unknown. forumanecdote
  • Microgram-chart confusion: A minority 2025 guide still wrote 10–50 mcg starts. Other threads immediately call that a unit mix-up. Treat mcg vs mg as a labeling landmine. forum
  • Framing: Every human figure below is research-chem / self-report / allometric chatter — not clinical dosing, not medical advice, not consumption guidance. No Phase 1 human dose-finding package is established for gray-market BAM15. forumtrial
  • Mouse alternate PK (Axelrod chronic): Peak serum ~5 µM, serum t½ ~3 h on food-admix regimen; distribution skewed to adipose depots in that design (liver still important elsewhere). animal
  • Mouse food admix (chronic standard): 0.05%, 0.10%, and 0.15% w/w in Western diet (Alexopoulos prevention); 0.1% w/w chosen for reversal and many follow-ons. Axelrod: ad lib 0.1% w/w HFD ≈ ~85 mg/kg/day consumed. Other designs use ~0.1–0.2% w/w or ~40 mg/kg/day effective intake when paired with semaglutide. Lower aged-muscle work: ~0.033% admix. animal
  • Mouse acute oral gavage (PK / OCR): 10 mg/kg often below clear OCR signal; 50 mg/kg and 100 mg/kg raise VO2; tissue distribution studies commonly use 50 mg/kg oral; solubility paste limits practical gavage above ~150–200 mg/kg. animal
  • Mouse oral PK numbers: ~67% oral bioavailability; ~1.7 h t½; Cmax ~8.2 µM after 10 mg/kg oral (Alexopoulos). Chronic admix overnight plasma often ~5–10 µM. animal
  • Mouse IP / other: Discovery kidney work and acute temp IP doses in the 0.1–1 mg/kg range (Axelrod temp study); some liver-lipid papers use ~10 mg/kg IP every other day × 4 weeks — not the community oral default. animal

How it may feel 11

  • Hours 0–3 (oral talk): Mouse OCR rise tracks PK (first 1–2 h strongest at 50–100 mg/kg oral); community self-reports range from nothing → mild warmth, restlessness, thirst, or light sweat. animalforum
  • Hours 3–6+: Mouse plasma/tissue levels decline over several hours; the 50 mg/kg oral distribution study sampled clearance over about 4 hours with a strong liver signal. That does not mean all drug was gone by hour 4. A person's “still warm” report is not a measured drug or effect half-life. animalanecdote
  • Days 1–7: Community logs describe tracking oral temperature, resting HR, sleep, GI, perceived heat and exercise capacity during early tolerability checks. Many older low-single-digit to teen-mg oral reports describe little felt change; this is an observation window, not a titration instruction. forum
  • Weeks 1–2: Mouse fat-mass curves and GTT improvements can appear within the first 1–2 weeks of continuous admix; human logs use this window for “anything happening?” checks under a true deficit. animalforum
  • Weeks 2–4: A community checkpoint for weight trends versus water/deficit noise; older social summaries also claim higher sleep temperature without stimulant buzz. One cross-posted account using 70 mg BAM15 with 250 mg SANA MVD1 described nothing initially, warmth in week 1 and weight/waist change by weeks 2–3 with sleep unchanged. Summer heat, co-use and uncontrolled intake prevent BAM15 attribution; another commenter was unsure anything was happening. forumanecdote
  • Weeks 4–8: Modal longer self-experiment block discussed for body-comp claims; mouse reversal studies also multi-week continuous feeding. animalforum
  • No change at about 3–4 weeks: Older troubleshooting discussion considers a true calorie deficit, split dosing based on short-half-life lore, taking with fat, and vendor identity/purity/assay. These are disputed explanations, not a proven sequence or dosing instructions. The protective warning remains: stop rather than blindly double the dose. forum
  • Pre-workout cap (2026 n=1): An X log moved BAM15 off pre-workout after perceived effort stuck ~80%; post-session or night-before sat better with the next lift. Mechanistic “don’t uncouple at peak ATP demand” talk, not a trial. anecdoteforum
  • Inject feel is harsher in sparse logs: One 2026 r/Biohackers oil-suspension diary called 20 mg inject palpitations + strong thermic effect, 5 mg milder, 1–2 mg the “handleable” band, and a 120 bpm rest-day after a bigger pin. Not a protocol. anecdote
  • Night sweats vs no heat: r/BAM15 includes bed-soaking sweats at ~300 mg AM and also “I feel nothing at 1000 mg.” Same name, opposite diaries. forumanecdote
  • Weeks 8–10+: Aged-mouse and long DIO runs extend here; continuous multi-month human safety unknown. animaltrial

Around the dose 6

  • Clock: Morning or split AM / early PM. Night doses are the sleep-heat complaint. forum
  • Training: 2026 n=1s argue against pre-hard-session uncoupling (effort feels capped). Post-workout or rest-day swallow is the newer habit; zone-2 still shows up as the “did anything happen” tell. forumanecdote
  • Food: Lipophilic — take-with-fat / MCT-oil talk is still the absorption folklore. Mouse chronic work was food-admix, not a fasted capsule. animalforum
  • After: Water, electrolytes, and an oral thermometer in harm-reduction posts. Warmth is an unreliable marker — mouse papers raised EE without core-temp spikes. animalforum
  • Avoid same-hours pile-on: Stims, T3/T4, and any DNP-class uncoupler are the hard-no list when heat and HR are the watch. forum
  • vs sitting still: Uncoupling-without-a-deficit logs are the usual “scale didn’t move” posts. forum

Cycles people discuss 10

  • Community short probe: 1–2 weeks for heat/HR/GI/sleep tolerability only. forum
  • Community body-comp blocks: 4–8 weeks on is the modal discussed cut-length run; many stop earlier if sides dominate. forum
  • Time off: Informal equal-time off or multi-week washouts appear in self-report culture; no pharmacology-backed human washout standard. forum
  • Continuous vs pulse: Daily through a cut is more common than true on/off pulsing; prep-only pulses also mentioned without consensus. forum
  • vs DNP culture: Historical DNP users sometimes ran short aggressive blasts; BAM15 threads often claim “milder longer” — still unproven and still uncoupler-class risk. forum
  • Mouse obesity prevention: Short dose-response runs ~7–8 days at 0.05–0.15% w/w. animal
  • Mouse obesity reversal: ~4 weeks WD conditioning then ~5 weeks 0.1% BAM15 (Alexopoulos); Axelrod chronic efficacy ~2–3 weeks on 0.1% HFD admix. animal
  • Mouse aged / sarcopenia windows: ~8–10 weeks continuous admix in aged obese or sarcopenia-oriented designs. animal
  • Mouse combo / MASH: ~8 weeks BAM15 ± MGL in GAN diet; atherosclerosis oral designs up to ~12 weeks. animal
  • Long-term human safety: Not established — multi-month/year continuous use has no clinical database. trial

Timing 10

  • Distribution: Early strong liver signal after 50 mg/kg oral with clearance over ~4 h from sampled tissues; Axelrod chronic work emphasizes adipose depot levels with lesser liver/heart/kidney. Brain exposure limited in partition talk — “not DNP-like CNS buildup” is a common safety narrative, still animal-only. animalforum
  • Human PK boundary: The two checked primary papers measure mouse plasma/serum exposure, not human oral bioavailability, half-life, Cmax or steady state. Older secondary blogs quote 4–6 hours as a human half-life; that remains unverified here and must not be treated as a measured human value. animalforum
  • Dosing logic discussed from PK: Short mouse coverage is invoked to explain split oral reports versus pulsatile exposure, not a validated human schedule. The mouse evidence is not a weekly depot model and cannot establish a human redosing interval. animalforum
  • Mouse oral t½ (primary): About 1.7 hours after 10 mg/kg oral gavage in C57BL/6J mice; oral bioavailability about 67% using the dose-normalized IV comparison (Alexopoulos, Nature Communications 2020). This is mouse parent-drug PK, not a human estimate. animal
  • Mouse serum t½ (chronic admix sampling): ~3 hours with peak serum ~5 µM (Axelrod EMBO Mol Med). animal
  • Cmax example: ~8.2 µM average Cmax after 10 mg/kg oral in the Alexopoulos PK design. animal
  • PD window: Acute OCR elevation largely within ~0–3 h post gavage at efficacious oral doses, matching short PK. animal
  • Why food admix exists: Low aqueous solubility + short t½ → continuous dietary exposure to hold micromolar plasma overnight in chronic studies. animal
  • Downstream biology: Transcriptional/metabolic adaptations (insulin sensitivity, liver lipid) in mice track multi-day continuous exposure, not single-peak “feel.” animal
  • Derivative direction: Labs explicitly chase longer t½ / better exposure analogs (e.g. SHS4121705 reported much longer mouse t½ than parent BAM15 in SAR writeups) because parent BAM15’s short half-life is a development bottleneck. animaltrial

More on what it is 9

  • Why people care: 2020 mouse papers (Alexopoulos et al. Nat Commun; Axelrod et al. EMBO Mol Med) showed fat loss / resistance to diet obesity with food intake and lean mass largely preserved and no core hyperthermia at efficacious doses — hence “safer DNP” forum/YouTube lore. animalforum
  • vs DNP (key bro distinction): BAM15 is more mitochondria-selective / broader OCR plateau in cells than classic DNP and did not raise rectal temperature at high acute oral doses in mice; DNP history includes narrow therapeutic window, hyperthermia deaths, cataracts. Mouse “safer” ≠ proven human safety. labanimalforum
  • What it is not: Not a GLP-1, stimulant thermogenic, thyroid hormone, SARM, or pharmacy weight-loss medicine. Often mis-shelved next to “peptides.” forumtrial
  • Core limitation (authors + community): Short mouse half-life (~1.7–3 h) + low aqueous solubility → food-admix in chronic papers; human gray-market oral powder/caps are extrapolation. animalforum
  • 2026 dose-camp split: Cautious charts still sit at ~5–30 mg oral. r/BAM15 and 250 mg-cap shops talk 50–100 mg then 400 mg+ “min effective.” Influencer BioBAM posts have pushed gram-per-day language. Same molecule name, three different conversations. forum
  • Not DNP, not proven safer in humans: Mouse “no fever at efficacious doses” is still the pitch. Human overdose series for BAM15 specifically are not established. animalforum
  • What it is: Synthetic small-molecule mitochondrial protonophore uncoupler (oxadiazolo-pyrazine / bis-fluoroaniline scaffold; CAS 210302-17-3). Research chem — not a peptide, not an approved fat-loss drug. trial
  • Mechanism (plain): Protons leak across the inner mitochondrial membrane so cells burn more fuel (raise OCR / energy expenditure) to make the same ATP. Mild uncoupling also lowers ROS in models. labanimal
  • Evidence level: Dense rodent obesity, clamp, liver, and aged-muscle package; academic SAR derivatives (e.g. SHS4121705, SHC517) aimed at better PK/NASH. No solid human RCT or approved label for weight loss as of research cut. trial

Stacks 14

  • Base stack first: Calorie deficit + protein + steps + lifting — every honest thread credits diet when scale moves. forum
  • SLU-PP-332 + BAM15: Most-named dual “mito” stack in 2025–2026 biohacker media — narrative: SLU builds oxidative/ERR “engine,” BAM15 forces more fuel burn. Some split SLU on training days / BAM15 on off days; others run both. No published combo safety. forum
  • 5-Amino-1MQ adjacency: Often listed in the same metabolic cart (NNMT + uncoupler theory); triple with SLU appears in influencer stacks. Attribution impossible. forum
  • GLP-1 / dual-agonist add-on talk: “Uncoupler when tirz/sema/reta stalls” or intentional intake↓ + EE↑ — mouse semaglutide+BAM15 papers fuel the theory; human layering may mask over-uncoupling fatigue and is unstudied for safety. animalforum
  • Cardarine / SR9009 / “exercise mimetic” cut stacks: Occasional forum pairing for recomp/cardio aesthetics; each agent has its own risk flags. forum
  • MOTS-c / SS-31 / NAD precursors (NMN, NR, NAD+): Mitochondrial-support narrative stacks; mechanistic coherence without combo trials. forum
  • L-carnitine / creatine / electrolytes: Harm-reduction self-report add-ons for substrate, lean-mass, and sweat losses — not BAM15-specific evidence. forum
  • Stimulants / yohimbine / high caffeine: Often discouraged — muddy heat, HR, sleep, and historical uncoupler+stim danger lore from DNP case reports. forum
  • Thyroid hormone (T3/T4): Strongly discouraged in cautious writeups — redundant metabolic-rate push and CV strain. forum
  • Hard no — DNP co-use: Overlapping uncoupling mechanism + narrow historical margin; never stacked in any responsible discussion. forum
  • Hard no — alcohol binge while uncoupled: Hepatic/mito stress narrative. forum
  • Reta / GLP add-on diaries: 2026 inject logs already on 7.5 mg reta + GH peptides still added BAM15 — extra thermic/HR risk with no combo trial. anecdote
  • Antioxidant folklore: Vitamin C / astaxanthin show up next to high-oral BAM15 cuts as “ROS cover.” Not BAM15 evidence. forum
  • MGL-3196 (resmetirom-class) preclinical: Published mouse MASH combo with 0.1% BAM15 — research only, not a bro stack SKU pair. animal

Access talk 5

  • RUO oral only: Capsules and powder labeled research-use / not for human consumption. Not a compounded pharmacy uncoupler and not an approved fat-loss drug. forum
  • Capsule strengths people mix up: 25 mg and 50 mg bottles sit next to 250 mg BioBAM-style SKUs. The mg on the cap is the whole argument. forum
  • Oil-suspension inject: Minority 2026 DIY route (palpitation diaries). Not the mouse oral-admix standard. forumanecdote
  • Shop shelf: Sold beside SLU-PP-332 / 5-Amino-1MQ metabolic carts. A COA is still not a human dose-finding study. forum
  • HU6 / controlled-DNP adjacency: 2026 X compared BAM15 to HU6 (a DNP prodrug with human Phase 2 liver-fat data). Different molecules; do not treat BAM15 as that program. forumtrial

Labs people mention 4

  • Oral temperature + resting HR: Harm-reduction posts check temp a few times a day and watch RHR — uncoupler-class habit, not a BAM15 label. forum
  • CMP / LFTs / CK: Mouse chronic panels were largely clean; self-experiment culture still pulls liver enzymes and CK if heat, dark urine, or exercise collapse shows. animalforum
  • Glucose: Preclinical glycemic improvements are why some stare at fasting glucose / a CGM. Human outcome data are not that. animalforum
  • No cancer-surveillance panel: Unlike cardarine’s tumor discourse, BAM15 watch-for is acute heat/HR/rhabdo class risk, not a screening protocol. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 16

  • Class risk (uncouplers): Over-uncoupling can produce hyperthermia that does not respond to ordinary antipyretics, CV strain, rhabdomyolysis, organ failure — DNP’s human death and cataract history is the cautionary class tale. BAM15 mouse data look cleaner; human overdose series for BAM15 specifically are not established. forumtrialanimal
  • Mouse “no hyperthermia” caveat: Core temp flat at published efficacious doses is encouraging preclinically — it does not prove zero thermic risk at arbitrary gray-market human mg or in heat/exercise/illness. animalforum
  • Self-report sides: Warmth, night sweats, thirst, mild fatigue, reduced high-intensity exercise tolerance, headache, nausea, sleep disruption, restlessness — sparse, confounded, purity-unknown. forumanecdote
  • Monitor talk (harm-reduction culture): Resting oral temperature pre-dose and 2–4 h post; RHR/BP trends; stop lore for persistent elevated temp, large RHR jumps, uncontrolled sweating, dark urine, confusion, or disproportionate exercise collapse — emergency care with honest disclosure if severe. forum
  • Hepatic / renal labs talk: Mouse chronic panels were largely clean (mild BUN shifts within reference in one study); human self-experiment culture still discusses CMP/LFTs/CK before and during longer runs because class risk remains. animalforum
  • Cataract / neuropathy unknown transfer: Documented with historical DNP; whether BAM15 shares those long-horizon toxicities is unknown. trialforum
  • Source risk: Mislabel, wrong potency, solvent contamination, and non-pharma powder on gray market. forum
  • Solubility / peak risk: Low solubility + short t½ can mean uneven exposure; “more mg” is not a rational efficacy ladder and may spike heat load. trialforum
  • Stimulant / thyroid / DNP stacking: Amplifies CV and thermic danger; strongest avoid list in community caution writeups. forum
  • Sport / military / policy: Uncouplers attract anti-doping and institutional scrutiny; status and testing evolve by organization — assume risk of prohibition. forum
  • Special populations: Pregnancy, cardiac disease, uncontrolled thyroid disease, prior heat illness, mitochondrial myopathy, eating disorders — treated as hard avoids in cautious educational writeups (no human trial clearance). forum
  • mg vs mcg mix-up: A 10–50 mcg chart next to a 250 mg capsule is how people 1000× themselves on paper. Confirm the unit before copying a log. forum
  • Gram-day watch: 2 g/day influencer talk is not a studied human window. Heat, HR, and exercise collapse are the class red flags even if mouse core temp was flat. forum
  • Inject HR spikes: Sparse oil-suspension logs reported palpitations and a 120 bpm rest-day after a 20 mg pin — another reason oral vs inject is not interchangeable. anecdote
  • Human safety gap: No established long-term human safety, therapeutic window, or Phase 3 obesity program for parent BAM15 as a consumer fat-loss agent. trial
  • Medical emergency framing: Suspected severe uncoupler toxicity → emergency evaluation; management is supportive cooling/fluids/ICU-level care in DNP literature, not a simple antidote. forumtrial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →